Urology
Volume 69, Issue 3 , Pages 479-484 , March 2007

Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens

  • Chia-Chi Lin

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Chih-Hung Hsu

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Chao-Yuan Huang

      Affiliations

    • Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Yu-Chieh Tsai

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Kuo-How Huang

      Affiliations

    • Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Ann-Lii Cheng

      Affiliations

    • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
    • Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan
    • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    • ,
  • Yeong-Shiau Pu

      Affiliations

    • Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
    • Corresponding Author InformationReprint requests: Yeong-Shiau Pu, M.D., Ph.D., Department of Urology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan.

Received 16 June 2006 ,Accepted 12 December 2006.

References 

  1. Roth BJ, Bajorin DF. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol. 1995;153:894–900
  2. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066–1073
  3. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050–1055
  4. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002;20:1361–1367
  5. Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220–228
  6. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3077
  7. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564–2569
  8. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–4608
  9. Sternberg CN, de MP, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006;42:50–54
  10. Lin CC, Hsu CH, Huang CY, et al. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity. Cancer. 2006;106:1269–1275
  11. Lin CC, Hsu CH, Huang CY, et al. Phase II trial of weekly paclitaxel, cisplatin plus infusional high-dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma. J Urol. 2007;177:84–89
  12. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  14. Cox D. Regression models and life tables. J R Stat Soc. 1972;34:187–220
  15. Chen CH, George SL. The bootstrap and identification of prognostic factors via Cox’s proportional hazards regression model. Stat Med. 1985;4:39–46
  16. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173–3181
  17. Bajorin D. The Phase III candidate: can we improve the science of selection?. J Clin Oncol. 2004;22:211–213
  18. Riley RD, Abrams KR, Sutton AJ, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003;88:1191–1198

PII: S0090-4295(06)02634-3

doi: 10.1016/j.urology.2006.12.010

Urology
Volume 69, Issue 3 , Pages 479-484 , March 2007

Article Tools

* Image Usage & Resolution